Jnana Therapeutics to Present Preclinical Data on its PKU Program at the 2023 Society for Inherited
Phase 1a clinical trial of JNT-517 in healthy volunteers approaching completionBOSTON--(BUSINESS WIRE)--Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, will present preclinical data for its lead...
Source: pharmiweb.com